Economic burden of select adverse events (AEs) in patients (Pts) with advanced urothelial cancer (aUC) treated with first-line (1L) systemic therapy.

被引：1
|
作者：
Grivas, Petros
Laliberte, Francois
Doleh, Yunes
O'Connor, Cristi
Duh, Mei Sheng
Shenolikar, Rahul
机构：
[1] Univ Washington, Seattle Canc Care Alliance, Seattle, WA 98195 USA
[2] Grp Anal Ltee, Montreal, PQ, Canada
[3] AstraZeneca, Gaithersburg, MD USA
[4] Anal Grp Inc, Boston, MA USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2019年 / 37卷 / 07期
关键词：
D O I：
10.1200/JCO.2019.37.7_suppl.363
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
363
引用
收藏
页数：1
相关论文
共 50 条
  • [31] Avelumab first-line (1 L) maintenance for advanced urothelial carcinoma (aUC): Results from patients with ≥12 months of treatment in JAVELIN Bladder 100
    Aragon-Ching, Jeanny B.
    Grivas, Petros
    Loriot, Yohann
    Bellmunt, Joaquim
    Pook, David W.
    Wang, Jing
    Michelon, Elisabete
    di Pietro, Alessandra
    Powles, Thomas
    Sridhar, Srikala S.
    ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY, 2022, 18 : 138 - 139
  • [32] Is first-line immune checkpoint inhibitors (ICI) beneficial to platinum-eligible patients (pts) with advanced urothelial carcinoma (aUC)? a meta-analysis.
    Cheng, Ce
    Chineke, Iloabueke Gabriel
    McBride, Ali
    Chipollini, Juan
    Gelmann, Edward Paul
    Recio-Boiles, Alejandro
    JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)
  • [33] Clinical outcomes of patients (Pts) with BRAF V600E-mutant metastatic colorectal cancer (mCRC) treated with first-line (1L) chemotherapy regimens
    Parikh, A.
    Tabernero, J.
    Vieira, M. C.
    Kponee-Shovein, K.
    Li, B.
    Cheng, M.
    Liu, J.
    Kang, H.
    Zhang, X.
    ANNALS OF ONCOLOGY, 2024, 35 : S44 - S45
  • [34] ELIOS: A multicentre, molecular profiling study of patients (pts) with epidermal growth factor receptor-mutated (EGFRm) advanced NSCLC treated with first-line (1L) osimertinib
    Piotrowska, Z.
    Ahn, M-J.
    Pang, Y. K.
    How, S. H.
    Kim, S-W.
    Voon, P. J.
    Cortinovis, D. L.
    De Castro Carpeno, J.
    Tiseo, M.
    Rodriguez Abreu, D.
    Ramalingam, S. S.
    Li, J.
    Servidio, L.
    Sadow, S.
    Hartmaier, R. J.
    Cho, B. C.
    ANNALS OF ONCOLOGY, 2022, 33 (07) : S1420 - S1421
  • [35] ELIOS: A multicentre, molecular profiling study of patients (pts) with epidermal growth factor receptor-mutated (EGFRm) advanced NSCLC treated with first-line (1L) osimertinib
    Piotrowska, Z.
    Ahn, M-J.
    Pang, Y-K.
    How, S. H.
    Sang-We, K.
    Voon, P. J.
    Cortinovis, D. L.
    Carpeno, J. De Castro
    Tiseo, M.
    Abreu, D. Rodriguez
    Ramalingam, S. S.
    Li, J.
    Servidio, L.
    Sadow, S.
    Hartmaier, R. J.
    Cho, B. C.
    ANNALS OF ONCOLOGY, 2022, 33 : S1581 - S1582
  • [36] HEALTH RESOURCE UTILIZATION (HRU) AND COSTS FOR METASTATIC RENAL CELL CARCINOMA (MRCC) PATIENTS TREATED WITH FIRST-LINE (1L) SYSTEMIC THERAPY IN THE UNITED STATES
    Mhatre, S.
    Lin, S.
    Surinach, A.
    Vohra, R.
    Satram-Hoang, S.
    Simpson, J.
    Wallen, H.
    Ogale, S.
    Gong, J.
    Pal, S. K.
    George, D. J.
    VALUE IN HEALTH, 2016, 19 (07) : A755 - A755
  • [37] Avelumab first-line (1L) maintenance therapy in advanced urothelial carcinoma: Final analysis from a real-world study in the UK.
    Jones, Robert Jones
    Shah, Yatri
    Birtle, Alison Jane
    Challapalli, Amarnath
    Chan, Joachim
    Enting, Deborah
    Hudson, Andrew
    Linch, Mark David
    Otter, Sophie
    Protheroe, Andrew
    Sharma, Anand
    Turner, Rufus
    Chengat Prakashbabu, Bhagyalakshmi
    Rice, Wendy
    Jedy-Agba, Elima Enaji
    JOURNAL OF CLINICAL ONCOLOGY, 2025, 43 (5_SUPPL)
  • [38] Post-treatment prognostic model for patients (pts) with metastatic urothelial cancer (UC) treated with first-line chemotherapy
    Galsky, Matt D.
    Moshier, Erin L.
    Krege, Susanne
    Lin, Chia-Chi
    Hahn, Noah M.
    Ecke, Thorsten
    Sonpavde, Guru
    Pond, Gregory Russell
    Godbold, James H.
    Oh, William K.
    Bamias, Aristotelis
    JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (06)
  • [39] ONCOLOGISTS' AND UROLOGISTS' PREFERENCES FOR FIRST-LINE (1L) TREATMENT OF LOCALLY ADVANCED/ UNRESECTABLE METASTATIC UROTHELIAL CARCINOMA (AUC): A DISCRETE CHOICE EXPERIMENT (DCE) CONDUCTED IN 5 EUROPEAN COUNTRIES
    Panattoni, L.
    Kearney, M.
    Land, N.
    Flottemesch, T.
    Sullivan, P.
    Kirker, M.
    Bharmal, M.
    Hauber, B.
    VALUE IN HEALTH, 2023, 26 (06) : S11 - S11
  • [40] Real-world time on treatment (rwTOT) with first-line (1L) enfortumab vedotin and pembrolizumab (EV plus P) after US Food and Drug Administration approval for advanced urothelial cancer (aUC).
    Mayer, Melanie
    Seewald, Nicholas
    Perez, Ernesto Ulloa
    Homet Moreno, Blanca
    Ramamurthy, Chethan
    Babcock, Aram
    Li, Haojie
    Mamtani, Ronac
    JOURNAL OF CLINICAL ONCOLOGY, 2025, 43 (5_SUPPL)
12345